当前位置: X-MOL 学术J. Am. Acad. Dermatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013
Journal of the American Academy of Dermatology ( IF 13.8 ) Pub Date : 2018-07-03 , DOI: 10.1016/j.jaad.2018.06.045
Frederick C. Morgan , Juanita Duran , Belen Fraile , Pritesh S. Karia , Jennifer Y. Lin , Patrick A. Ott , Emily Stamell Ruiz , David M. Wang , Yichen Zhang , Chrysalyne D. Schmults

Background

Temporal analyses of skin cancer costs are needed to examine how expenditure differences between diagnoses are changing.

Objective

To tabulate the costs of skin cancer–related care (SCRC), including both screening and treatment, at an academic cancer center at 2 time points.

Methods

Cost data (insurance and patient payments) at an academic cancer center from 2008 and 2013 were queried for International Classification of Diseases, Ninth Revision, codes pertaining to skin cancer. Screening costs were separated from treatment costs through associated Current Procedural Terminology codes.

Results

The total annual cost of SCRC increased by 64%, the number of patients receiving SCRC increased by 45%, and the mean cost per patient treated increased by 13%. Screening accounted for 17% and 16% of total annual costs in 2008 and 2013, respectively. The mean cost per patient with melanoma increased by 84%, which was the largest increase among skin cancer diagnoses. In 2013, the few patients with melanoma who were treated with ipilimumab (n = 48 [4% of patients with melanoma]) accounted for 42% of melanoma treatment costs and 20% of SCRC costs.

Limitations

Prescription costs were unavailable.

Conclusions

Melanoma costs have increased as a result of the introduction of ipilimumab. Ongoing studies are needed to monitor the cost-effectiveness of SCRC at a national level.



中文翻译:

2008年与2013年马萨诸塞州癌症中心皮肤癌筛查和治疗费用的比较

背景

需要对皮肤癌费用进行时间分析,以检查诊断之间的支出差异如何变化。

客观的

要在两个时间点在学术癌症中心中列出皮肤癌相关护理(SCRC)的费用,包括筛查和治疗费用。

方法

查询了2008年至2013年学术癌症中心的费用数据(保险和患者付款),以查询《国际疾病分类》第九版(与皮肤癌有关的代码)。通过相关的现行程序术语代码将筛查费用与治疗费用分开。

结果

SCRC的年度总费用增加了64%,接受SCRC的患者人数增加了45%,每位接受治疗的患者的平均费用增加了13%。筛查分别占2008年和2013年年度总费用的17%和16%。每位黑色素瘤患者的平均费用增加了84%,这是皮肤癌诊断中最大的增加。2013年,接受伊匹木单抗治疗的少数黑色素瘤患者(n = 48 [黑色素瘤患者的4%])占黑色素瘤治疗费用的42%和SCRC费用的20%。

局限性

处方费用不可用。

结论

由于引入了ipilimumab,黑色素瘤的费用增加了。需要进行持续的研究以在国家一级监测SCRC的成本效益。

更新日期:2018-07-03
down
wechat
bug